---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058190"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:24:27.507275+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iterum submits NDA for oral sulopenem; Q1 net loss narrows to $7.1M, cash runway into 2025

## Summary
- NDA resubmitted in April 2024 for oral sulopenem; FDA action expected early Q4 2024.
- Cash, equivalents & short-term investments $18.2M at March 31, 2024; ATM raised $7.2M in Q1.
- Net loss $7.1M in Q1 2024 vs $9.9M in Q1 2023; non-GAAP net loss $5.8M vs $7.4M.
- R&D expenses fell to $4.0M from $6.4M as REASSURE trial enrollment completed in October 2023.
- Cash runway extended into 2025, including through expected PDUFA date in early Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-058190
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/itrm-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058190
- JSON: https://secwatch.observer/filing/0000950170-24-058190.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058190.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported first quarter ended March 31, 2024 results: net income $7.1 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $7.1 million
  - Result: reported results
  source text: iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.